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We thank Zhang and Hei for their insightful comments on our study of mesenchymal 
stromal cells (MSCs) in a sheep model of extracorporeal membrane oxygenation (ECMO) 
and Acute Respiratory Distress Syndrome (ARDS) (1).  Their principal thesis is that the 
adverse interaction which we observed, between MSCs and the membrane oxygenator, may 
be overcome by substituting MSCs with MSC-derived exosomes. This proposal has merit. 
The MSC secretome has been of interest as a therapeutic for some time, in particular; MSC-
derived extracellular vesicles (EVs) (2), MSC-derived exosomes (3), and MSC conditioned 
media (4). These each offer several theoretical advantages over conventional MSC therapy. 
First, contents of the secretome do not express Major Histocompatibility Complex (MHC) 
antigens, removing concerns about immunogenicity. Second, components of the secretome 
are, in general, easier to store and less susceptible to the adverse effects of storage on 
efficacy. Third, components of the MSC secretome are much smaller than the cells from 
which they are derived, and thus less likely to be subject to ‘trapping’ in the pulmonary 
circulation (5). Recently, an early phase trial of an MSC-derived exosome treatment for 
severe COVID-19 has been reported with no apparent safety issues (6). However, there are 
some unresolved issues which should be borne in mind. 
Paracrine actions are the principle means by which MSCs exert benefit in ARDS, although 
several alternative mechanisms have been described, such as mitochondrial transfer from 
MSCs to damaged alveolar epithelial cells (7). The inability of secretome-based therapies to 
reproduce these actions may limit their efficacy (8,9). The translation of MSC secretome-
based therapies is also limited by challenges in scaling manufacturing for clinical purposes, 
an issue which is overcome by the use of induced pluripotent cell-derived MSCs (iPSC MSCs), 
like those used in our study (1). With specific regard to our study, the observation that 
pulmonary emboli were more frequent in the iPSC-derived MSC group, may not be uniquely 
associated with the use of a cell-based therapy. A variety of pre-clinical studies have 
described the pro-coagulant activity of MSC-derived EVs (10, 11). 
Despite these caveats, Zhang and Hei’s point is well made and highlights the work that is still 
required to successfully advance cell-therapy for ARDS, especially in the context of 
extracorporeal organ support. We hope that our study illustrates the usefulness of clinically 
relevant, high-fidelity animal models in advancing these efforts.  
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